Ann: Final Set of Interim Data from PXS-5505 in Myelofibrosis, page-7

If you look back for the last 10 years, Pharmaxis has always been able to have this kind of "positive" media coverage and articles, however their expensive, time consuming trail results only sank the share price more than 80%.
seems their pipelines are at most "interesting" to the big pharmas, but not good enough to land any deals (since BI thrown back their PXS - 4728 in 2019).
I am sure if Gary Philips was truly "extremely excited" about those results, or just to talk it up for another CR for the endless such trails in the next 5 years.